Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;18(6):e13342.
doi: 10.1111/irv.13342.

Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023

Jessie R Chung  1 , Philip Shirk  1 , Manjusha Gaglani  2   3 , Manohar B Mutnal  2   3 , Mary Patricia Nowalk  4 , Krissy Moehling Geffel  4 , Stacey L House  5 , Tara Curley  5 , Karen J Wernli  6   7 , Erika L Kiniry  6 , Emily T Martin  8 , Ivana A Vaughn  9 , Vel Murugan  10 , Efrem S Lim  11 , Elie Saade  12 , Kiran Faryar  13 , Olivia L Williams  14 , Emmanuel B Walter  14 , Ashley M Price  1 , John R Barnes  1 , Juliana DaSilva  1 , Rebecca Kondor  1 , Sascha Ellington  1 , Brendan Flannery  1
Affiliations

Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023

Jessie R Chung et al. Influenza Other Respir Viruses. 2024 Jun.

Abstract

Background: The 2022-23 US influenza season peaked early in fall 2022.

Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design.

Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval -9%, 54%); low late-season activity precluded estimation for most subgroups.

Conclusions: 2022-23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.

Keywords: influenza; vaccination; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

EBW has received research funding from Pfizer, Moderna, Seqirus, Najit Technologies, and Clinetic for the conduct of clinical research studies. He has also received support as an advisor to Vaxcyte, consultant to ILiAD Biotechnologies, and DSMB member for Shionogi. MPN and KMG have received research grant funding from Sanofi Pasteur not related to this work. MG has received research grant funding from CDC, Vanderbilt University, Westat, and Abt Associates not related to this work. SLH has received funding from Seegene Inc., Abbott, Healgen, Roche, CorDx, Hologic, Cepheid, Janssen, and Wondfo Biotech not related to this work. EAS has received funding from Protein Sciences Corporation and Johnson and Johnson not related to this work. KAF has received funding from the Gilead FOCUS program, the Cuyahoga County Board of Health, and the Ohio Department of Health.

Figures

FIGURE 1
FIGURE 1
Distributions of influenza A(H1N1)pdm09, A(H3N2), and B/Victoria HA clades among US viral surveillance data from US Flu VE Network states (N = 2304) versus sequenced US Flu VE Network specimens (N = 55), December 2022–April 2023.
See this image and copyright information in PMC

References

    1. US Centers for Disease Control and Prevention , “Influenza Activity in the United States During the 2022–23 Season and Composition of the 2023–24 Influenza Vaccine,” (2023), [cited 2023 October 23], https://www.cdc.gov/flu/spotlights/2023‐2024/22‐23‐summary‐technical‐rep....
    1. National Foundation for Infectious Diseases ,” US Health Officials Urge Vaccination to Help Protect Against a Potentially Severe Flu Season,” (2022), https://www.nfid.org/us‐health‐officials‐urge‐vaccination‐to‐help‐protec....
    1. Grohskopf L. A., Blanton L. H., Ferdinands J. M., et al., “Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices ‐ United States, 2022‐23 Influenza Season,” Morbidity and Mortality Weekly Report 71 (2022): 1. - PMC - PubMed
    1. White E. B., O’Halloran A., Sundaresan D., et al., “High Influenza Incidence and Disease Severity Among Children and Adolescents Aged <18 Years ‐ United States, 2022‐23 Season,” Morbidity and Mortality Weekly Report 72, no. 41 (2023): 1108–1114. - PMC - PubMed
    1. US Centers for Disease Control and Prevention , “US Flu VE Network,” (2023), [cited 2023 Dec 27], https://www.cdc.gov/flu/vaccines‐work/us‐flu‐ve‐network.htm.

Publication types

MeSH terms

Substances